Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.

Leo I GordonJason B KaplanRakesh PopatHoward A BurrisSilvia FerrariSumit MadanManish R PatelGiuseppe Gritti Dima El-Sharkawi Ian ChauJohn A RadfordJaime Pérez de OteyzaPier Luigi ZinzaniSwaminathan IyerWilliam TownsendReem KarmaliHarry MiaoIgor ProscurshimShining WangYujun WuKate StumpoYaping ShouCecilia Carpio Francesc Bosch

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

TAK-659 has single-agent activity in patients with B-cell lymphoma. Further studies of the drug in combination, including an evaluation of the biologically optimal and safest long-term dose and schedule, are warranted.

Keyphrases

diffuse large b cell lymphoma
tyrosine kinase
acute myeloid leukemia
emergency department
clinical trial
drug induced
phase ii